Market Overview - The Shanghai Composite Index fell by 0.70% on June 27, with 18 out of the 28 sectors experiencing gains, led by the metals and communications sectors, which rose by 2.17% and 1.79% respectively [2] - The banking and public utilities sectors saw the largest declines, with drops of 2.95% and 1.01% respectively [2] - The computer industry also experienced a decline of 0.36% [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 19.41 billion yuan, with 8 sectors seeing net inflows [2] - The communications sector had the highest net inflow of 2.579 billion yuan, followed by the electronics sector with a net inflow of 2.435 billion yuan and a daily increase of 0.92% [2] - The computer industry had the largest net outflow, totaling 6.630 billion yuan, followed by the defense and military industry with a net outflow of 2.891 billion yuan [2] Computer Industry Specifics - Within the computer industry, there are 336 stocks, with 141 rising and 188 falling on the day [3] - A total of 111 stocks in the computer sector saw net inflows, with 5 stocks exceeding 100 million yuan in net inflow; leading was Dawi Technology with 671 million yuan, followed by Jinzhen Shares and Weining Health with 321 million yuan and 256 million yuan respectively [3] - The stocks with the largest net outflows included Zhinan Zhen with 683 million yuan, Zhongke Shuguang with 375 million yuan, and Xinguodu with 372 million yuan [3][5] Top Gainers in Computer Industry - The top gainers in the computer sector included: - Dawi Technology: +6.61%, turnover rate 28.45%, net inflow 671.13 million yuan - Jinzhen Shares: +4.51%, turnover rate 15.87%, net inflow 321.27 million yuan - Weining Health: +9.84%, turnover rate 13.46%, net inflow 255.91 million yuan [4] Top Losers in Computer Industry - The top losers in the computer sector included: - Zhinan Zhen: -3.41%, turnover rate 15.62%, net outflow -682.78 million yuan - Zhongke Shuguang: -1.35%, turnover rate 2.62%, net outflow -375.17 million yuan - Xinguodu: -2.94%, turnover rate 22.68%, net outflow -371.73 million yuan [5]

Group 1 - The core viewpoint of the article highlights a significant increase in the performance of medical information technology concept stocks, with notable gains in specific companies [1] - Weining Health experienced a rise of over 10%, indicating strong market interest and investor confidence in the sector [1] - Other companies such as Dian Diagnostics and Chuangye Huikang also saw increases of over 5%, reflecting a broader positive trend in the medical information technology industry [1] Group 2 - Additional companies that followed the upward trend include Sichuang Medical, Guoxin Health, Jiuyuan Yinhai, Wanda Information, and Saili Medical, showcasing a collective movement within the sector [1]

Group 1 - The smart medical sector is experiencing a significant upward trend, with notable stock price increases for several companies [1] - Jincheng Pharmaceutical (300233) has seen its stock rise by over 10% [1] - Heertai (002402) and Weining Health (300253) have both increased by over 9% [1] - Yaoshi Technology (300725) has experienced a stock price increase of over 5% [1] - Other companies such as Yuandong Biology and Chengdu Xian Dao are also showing upward movement [1]

后不会对公司股本造成影响。 卫宁健康科技集团股份有限公司关于 2022 年股权激励计划部分期权注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）第六届董 事会第十四次会议审议通过了《关于注销部分股票期权的议案》《关 于 2022 年股权激励计划首次授予期权第三个行权期行权条件未成就 的议案》《关于 2022 年股权激励计划预留授予期权第二个行权期行权 条件未成就的议案》，同意注销 2022 年股权激励计划首次授予期权 25,284,320 份、预留授予期权 6,308,806 份，其中：23 名首次授予 激励对象、8 名预留授予激励对象因个人原因离职，不再具备激励对 象资格，同意注销已授予尚未行权的首次授予期权 1,952,680 份、预 留授予期权 705,175 份；公司 2024 年经营业绩未达到公司层面的业 绩考核指标，首次授予期权第三个行权期、预留授予期权第二个行权 期行权条件未成就，同意注销首次授予期权第三个行权期已获授期权 23,331,640 份、预留授予期权第二个行权期已获授期权 ...

Core Viewpoint - The credit rating report for Weining Health Technology Group indicates a stable outlook despite recent performance declines, driven by challenges in innovative business segments and competitive pressures in the healthcare information technology industry [3][5][6]. Company Overview - Weining Health is recognized as a leading enterprise in the domestic healthcare information industry, maintaining a market share of 13.4% in the core hospital diagnostic system sector as of 2023 [17]. - The company continues to implement its "1+X" strategy, focusing on the WiNEX series products and digital health applications [15][17]. Financial Performance - The company's revenue for 2024 was reported at 3.45 billion yuan, a decrease of 12.05% year-on-year, with a net profit of -0.03 billion yuan [4][16]. - The financial structure remains robust, with total debt at 11.62 billion yuan and equity at 60.30 billion yuan as of March 2025 [4][5]. - The company’s cash flow from operating activities was negative at -0.26 billion yuan, indicating liquidity challenges [4]. Business Segments - The healthcare information technology segment remains the primary revenue source, contributing 2.92 billion yuan in 2024, but faced a decline of 14.17% [16][19]. - The internet healthcare segment showed slight revenue growth, but overall performance is still impacted by losses in innovative business areas [24][25]. Market Environment - The healthcare information technology industry is experiencing growth, with a projected market size of 230.3 billion yuan in 2024, driven by policy support and AI technology integration [10][11]. - The industry faces high competition and rapid technological changes, necessitating continuous innovation and adaptation from companies [6][10]. Innovation and R&D - The company has been focusing on enhancing its R&D capabilities, with a significant investment in AI and digital health solutions, although R&D personnel and investment amounts have decreased recently [23][24]. - The introduction of new products, such as the WiNGPT2.8 and WiNEX Copilot 2.1, aims to strengthen the company's competitive position in the market [23]. Customer Base and Sales - The primary customers are public hospitals and health management departments, with a low customer concentration risk as the top five clients account for only 5.61% of total sales [19][21]. - The sales model primarily involves direct sales through competitive bidding, with payment structures that include prepayments and milestone payments [18]. Future Outlook - The company maintains a stable credit rating outlook, supported by its competitive advantages in core hospital systems and ongoing technological advancements [5][6]. - However, the future profitability of innovative business segments remains uncertain, with ongoing losses and the need for strategic adjustments [24][25].

卫宁健康科技集团股份有限公司 及相关债券2025年跟踪评级报告 中鹏信评【2025】跟踪第【368】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授 ...

Core Insights - The stock price of Weining Health closed at 8.88 yuan on June 23, with a rise of 1.72%, resulting in a rolling PE ratio of 256.63 times and a total market capitalization of 19.648 billion yuan [1] - The average PE ratio for the software development industry is 113.34 times, with a median of 80.95 times, placing Weining Health at the 172nd position in the industry ranking [1] - The net inflow of main funds for Weining Health on June 23 was 19.8053 million yuan, but over the past five days, there was a total outflow of 104.0014 million yuan [1] Company Overview - Weining Health Technology Group Co., Ltd. focuses on integrated solutions in the healthcare sector, providing research, sales, and technical services [1] - The company's main products include software and services, hardware sales, and internet healthcare solutions [1] Financial Performance - In the first quarter of 2025, Weining Health reported an operating revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit of 5.2894 million yuan, down 68.18% year-on-year, with a gross profit margin of 34.46% [1]

Core Viewpoint - The company announced the cancellation of certain stock options due to unmet performance conditions and the departure of some incentive recipients, impacting the 2022 stock option incentive plan [1][14][16]. Summary by Sections Stock Option Incentive Plan Overview - The 2022 stock option incentive plan was approved at the first extraordinary general meeting, allowing for a total of 33,000,000 stock options to be granted [1][4]. - The plan includes four exercise periods with specific performance targets based on net profit growth from 2021 [1][3]. Performance Conditions - For the first exercise period, the net profit growth rate must be at least 24% for 2022; for the second, at least 66% for 2023; for the third, at least 180% for 2025 [2][3]. - If the performance targets are not met, the corresponding stock options will be canceled [3][14]. Adjustments and Cancellations - Due to the departure of 23 recipients and performance issues, a total of 31,593,126 stock options will be canceled, including 2,657,855 options from departing recipients and 28,935,271 options due to unmet performance conditions [14][16]. - The exercise price for the stock options has been adjusted multiple times, currently set at 5.67 yuan per share [12][14]. Impact on the Company - The cancellation of stock options is not expected to affect the implementation of the 2022 incentive plan or the stability of the core management team, nor will it have a substantial impact on the company's financial status and operational results [14][15]. Legal and Procedural Compliance - The company has ensured that the cancellation process complies with relevant laws and regulations, and necessary approvals have been obtained [16][17].

2022 年股权激励计划首次授予期权第三个行权期、预留授予 期权第二个行权期行权条件未成就 及注销部分股票期权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300253 证券简称：卫宁健康 公告编号：2025-053 卫宁健康科技集团股份有限公司关于 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年 6 月 19 日召开第六届董事会第十四次会议，审议通过了《关于注销 部分股票期权的议案》、《关于 2022 年股权激励计划首次授予期权第 三个行权期行权条件未成就的议案》、《关于 2022 年股权激励计划预 留授予股票期权第二个行权期行权条件未成就的议案》，鉴于部分激 励对象离职、2024 年行权条件未成就，同意注销部分股票期权。现 将相关事项公告如下： 一、2022 年股权激励计划简述及已履行的相关审批程序 （一）股权激励计划简述 2022 年股权激励计划经公司 2022 年 10 月 17 日召开的 2022 年 第一次临时股东大会审议通过,简述如下： 1、股票来源：公司向激励对象定向发行公司 A 股普通股 2、授予的数量： ...

上海市广发律师事务所 关于卫宁健康科技集团股份有限公司 2022 年股权激励计划相关事项的法律意见 致：卫宁健康科技集团股份有限公司 上海市广发律师事务所（以下简称"本所"）接受卫宁健康科技集团股份有 限公司（以下简称"公司"）的委托，作为其 2022 年股票期权激励计划（以下 简称"2022 年股权激励计划"）的专项法律顾问，就本次 2022 年股权激励计划 相关事项，根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券 法》"）、《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）颁布的《上市公司股权激 励管理办法（2025 年修正）》（以下简称"《管理办法》"）、《深圳证券交易 所创业板股票上市规则（2025 年修订）》（以下简称"《上市规则》"）、《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理（2025 年修订）》 （以下简称"《创业板自律监管指南第 1 号》"）等法律、法规、规范性文件以 及《卫宁健康科技集团股份有限公司章程》（以下简称"《公司章程》"）、《卫 宁健康科技集团股份有限公司 2022 ...